British journal of clinical pharmacology · 2026
Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model-based simulation of the positioning imatinib for pulmonary arterial hypertension trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Said Medhat M, de Mooij Robert B, Jiao Dian, Ovelgonne Reitze J, Biram Rami, Delgado-SanMartin Juan, Rothman Alexander M K, Villar Sofia S, Roussakis Andreas A, Aman Jurjan, Mathôt Ron A A, Swart Eleonora L, Wilkins Martin R, Bartelink Imke H
Аннотация
AIMS: Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose-dependent toxicity has limited its clinical development. We aimed to quantify the dose-efficacy-toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
METHODS: We analysed data from the Phase II PIPAH trial (17 enrolled; 15 contributed pharmacokinetic and safety data, 11 daily hemodynamic data). Total pulmonary resistance (TPR) was described using a turnover model and recurrent adverse events (AEs) using a repeated time-to-event model.
RESULTS: Simulations showed that TPR reduction was dose-dependent ( E max 50%; E D 50 247 mg), whereas AE risk increased nonlinearly with dose ( E D 50 307 mg). Although a cumulative dose of 2400 mg produced similar TPR reductions, 300 mg once daily achieved a 20% reduction earlier than 200 mg (8 vs. 12 weeks) with only a modest increase in AE burden.
CONCLUSIONS: Simulations support initiating treatment at 200 mg once daily with escalation to 300 mg after 8-12 weeks in patients who tolerate treatment.
METHODS: We analysed data from the Phase II PIPAH trial (17 enrolled; 15 contributed pharmacokinetic and safety data, 11 daily hemodynamic data). Total pulmonary resistance (TPR) was described using a turnover model and recurrent adverse events (AEs) using a repeated time-to-event model.
RESULTS: Simulations showed that TPR reduction was dose-dependent ( E max 50%; E D 50 247 mg), whereas AE risk increased nonlinearly with dose ( E D 50 307 mg). Although a cumulative dose of 2400 mg produced similar TPR reductions, 300 mg once daily achieved a 20% reduction earlier than 200 mg (8 vs. 12 weeks) with only a modest increase in AE burden.
CONCLUSIONS: Simulations support initiating treatment at 200 mg once daily with escalation to 300 mg after 8-12 weeks in patients who tolerate treatment.